Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
M Nakhjavani, S Shigdar - Pharmacological research, 2022 - Elsevier
Triple-negative breast cancer (TNBC) has the worst prognosis among the subtypes of breast
cancer, with no targeted therapy available. Immunotherapy targeting programmed cell death …
cancer, with no targeted therapy available. Immunotherapy targeting programmed cell death …